Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IP6K2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The IP6K2 protein also known as inositol hexakisphosphate kinase 2 functions mechanically as an enzyme that converts inositol hexakisphosphate (IP6) into diphosphoinositol pentakisphosphate (IP7). It has a molecular mass of about 55 kDa. This kinase is widely expressed in various tissues with significant levels found in the brain and testes. IP6K2 activity plays a role in cellular energy homeostasis and signaling.
Biological function summary
IP6K2 influences several cellular processes including apoptosis and cell cycle regulation. It operates as a part of protein complexes that mediate the synthesis of inositol pyrophosphates which are important secondary messengers in cells. Through these roles IP6K2 helps regulate physiological functions such as insulin signaling and energy balance. Its interactions with various binding partners also enable it to influence cell survival and growth parameters.
Pathways
IP6K2 is actively involved in the inositol phosphate metabolism and apoptosis pathways. Inositol phosphate metabolism involves a range of signaling molecules where IP6K2 contributes to the generation of key signaling lipids. It works in conjunction with other kinases such as IP6K1 and phosphatidylinositol 3-kinase (PI3K) facilitating complex cellular activities. Through these pathways IP6K2 modulates processes that are essential for maintaining cell viability and proper cellular responses to external stimuli.
Dysregulation of IP6K2 has associations with several conditions including cancer and metabolic disorders. Altered IP6K2 function can influence cancer development by affecting apoptotic pathways where it interacts with key proteins such as p53 to regulate cell death. In metabolic disorders the kinase's role in insulin signaling connects it to metabolic issues like type 2 diabetes as its involvement in signal transduction impacts glucose homeostasis and insulin sensitivity.
